Co-Authors
This is a "connection" page, showing publications co-authored by MARIA SUAREZ-ALMAZOR and JASVINDER SINGH.
Connection Strength
1.702
-
Reliability and clinically important improvement thresholds for osteoarthritis pain and function scales: a multicenter study. J Rheumatol. 2014 Mar; 41(3):509-15.
Score: 0.471
-
Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial. PLoS Med. 2019 05; 16(5):e1002800.
Score: 0.170
-
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017 05 08; 5:CD012657.
Score: 0.148
-
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017 03 10; 3:CD012591.
Score: 0.146
-
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May; 64(5):625-39.
Score: 0.105
-
Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J. 2010; 128(5):309-10.
Score: 0.089
-
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009 Nov 24; 181(11):787-96.
Score: 0.088
-
Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009 Oct 07; (4):CD007848.
Score: 0.088
-
Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials. Semin Arthritis Rheum. 2024 Apr; 65:152381.
Score: 0.059
-
OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments. Semin Arthritis Rheum. 2024 Apr; 65:152344.
Score: 0.059
-
Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group. Semin Arthritis Rheum. 2023 12; 63:152288.
Score: 0.058
-
Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. Semin Arthritis Rheum. 2021 06; 51(3):593-600.
Score: 0.049
-
OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions. J Rheumatol. 2019 10; 46(10):1409-1414.
Score: 0.042
-
Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. Trials. 2018 Mar 27; 19(1):204.
Score: 0.039
-
Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2017 06; 46(6):699-708.
Score: 0.035
-
Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop. J Rheumatol. 2015 Oct; 42(10):1962-1970.
Score: 0.032
-
OARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group. J Rheumatol. 2011 Aug; 38(8):1765-9.
Score: 0.025